CSL Behring has reported results from a pharmacokinetic study of novel investigational recombinant coagulation single-chain factor VIII (rVIII-SingleChain), which demonstrated advantages over multi-chain rFVIII for the treatment of Haemophilia A.
The study, part of the AFFINITY clinical trial programme, demonstrated an improved half-life of rVIII-SingleChain against the comparator, octocog alfa, in addition to a safety and efficacy profile that supports progress to late-stage clinical development.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Medical University of Vienna, Austria, professor Dr Ingrid Pabinger-Fasching said that the data suggests that the recombinant single-chain design for Factor VIII may help address the need for haemophilia A treatment with a longer half-life.
"A treatment with an improved half-life has the potential to increase the quality of life for those with severe hemophilia A by reducing the number of factor VIII protein infusions required to restore normal blood clotting," Pabinger-Fasching added.
The pharmacokinetic (PK) measurements were carried out for more than 72 hours for both octocog alfa and rVIII-SingleChain on a total of 27 adult haemophilia A patients, subsequent to a single infusion of 50 IU/kg body weight of each of the compounds, respectively.
The objectives were to characterise the PK profile of rVIII-SingleChain, the PK comparison of rVIII-SingleChain to octocog alfa on the basis of FVIII activity, and the characterisation of the safety profile of rVIII-SingleChain.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPK parameters were calculated for baseline-corrected FVIII activity using a non-compartmental model analysis with WinNonlin Phoenix under the plasma activity-time curve from time zero to the last quantifiable concentration.
Additional parameters include the area under the plasma activity-time curve from time zero to infinity, observed maximum plasma activity after drug administration, incremental recovery (IU/mL/IU/kg) defined as FVIII activity (IU/mL) obtained 30 minutes following infusion, clearance and terminal elimination half-life.
CSL global clinical research and development senior vice president Dr Russell Basser said: "As part of our commitment to developing effective therapies to treat hemophilia, we sought to develop a novel recombinant single-chain Factor VIII design that improves the stability and half-life of factor VIII."
